Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials

Published:2018-09-06 Issue:6 Volume:78 Page:559-567
ISSN:0340-1855
Container-title:Zeitschrift für Rheumatologie
language:en
Short-container-title:Z Rheumatol

Author:

Bae S.-C.,Lee Y. H.

Publisher

Springer Science and Business Media LLC

Subject

Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s00393-018-0531-5.pdf

Reference45 articles.

1. Aletaha D, Landewe R, Karonitsch T et al (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Care Res 59(10):1371–1377

2. Brown S, Hutton B, Clifford T et al (2014) A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL. Syst Rev 3(1):110

3. Burmester GR, Benda B, Gruben D et al (2013) Tofacitinib for rheumatoid arthritis—Authors’ reply. Lancet 381(9880):1812–1813

4. Caldwell DM, Ades A, Higgins J (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331(7521):897

5. Catalá-López F, Tobías A, Cameron C et al (2014) Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int 34(11):1489–1496

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis;Pharmacology;2023

2. Safety and efficacy in the nursing care of people with rheumatic diseases on janus kinase inhibitor therapy;Rheumatology International;2022-08-18

3. Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis;Journal of Clinical Medicine;2022-07-30

4. Rheumatoid Arthritis and JAK-STAT Inhibitors: Prospects of Topical Delivery;Current Drug Therapy;2022-04

5. Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients;International Journal of Molecular Sciences;2022-01-23